Apogee Therapeutics, Inc. has initiated dosing in its first clinical trial for AGP777, its lead product candidate for atopic dermatitis and other inflammatory diseases.
AI Assistant
APOGEE THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.